

## **Stempeutics partners with Kemwell for global development and commercialization of stem cell therapeutics**

- ✓ Stempeutics has entered into strategic alliance with Kemwell Biopharma for development and commercialization of its flagship product Stempeucel®
- ✓ Under this alliance, Kemwell is investing up to Rs. 950 Million (~USD 14 Million) in Stempeutics over a period of five years based on certain milestones
- ✓ Kemwell will establish a cGMP manufacturing facility in Bangalore for global distribution of cell therapy products
- ✓ Through this alliance, the companies will leverage their expertise to increase access to these innovative medicines for patients in India and globally

**India, Bengaluru, July 22<sup>nd</sup>, 2019:** Stempeutics Research, a group company of Manipal Education and Medical Group (MEMG), announced today that it has signed a strategic deal with Kemwell Biopharma for global commercialization of its stem cell product Stempeucel®. Under this agreement, Kemwell will take a minority stake in Stempeutics and invest up to Rs 950 Million based on certain milestones as well as establish a world class cGMP cell therapy manufacturing facility at Kemwell's facility in Bangalore for contract manufacturing of cell therapy products.

Currently Stempeutics is working on three key indications i.e. Critical Limb Ischemia (CLI), Osteoarthritis (OA) and Diabetic Foot Ulcer (DFU). For marketing the products in India, it has partnered with Cipla for the CLI indication and with Alkem Labs for OA indication. Stempeutics is now exploring registration and commercialization of Stempeucel® in the developed markets i.e. the US, Europe and Japan and has initiated discussions with US FDA, EMA and Japan PMDA. Funds received from Kemwell will be utilized for achieving key regulatory milestones in the US, Europe and Japan.

Commenting on the Kemwell collaboration, **Dr Ranjan Pai, Chairman**, Manipal Education & Medical Group said, "We are progressing well towards our goal of bringing stem cell-based products for unmet medical needs in the Indian market by 2020. Stempeutics has done pioneering work in stem cells R&D and by far, it is the first stem cell company in Asia to demonstrate significant clinical outcomes in CLI. The synergistic combinations of Kemwell & Stempeutics will accelerate the development of novel stem cell-based products for patients and transform India into a global player in stem cell therapeutics".

**Mr. Anurag Bagaria, Chairman and CEO**, Kemwell added "We believe that Stem Cells will become a major branch of medical treatment and will become a standard of care for

challenging diseases. Kemwell is looking forward in building a world-class cGMP facility in Bangalore and make India as an emerging hub for cell therapy manufacturing. We are happy in partnering with Stempeutics because of their strength in developing innovative stem cell products starting from basic research, preclinical studies, large scale manufacturing and conducting multi-centre clinical studies meeting international standards.”

**Chandru Chawla, Executive Vice President Cipla and Board Member, Stempeutics** added “Stempeutics has been at the cutting edge of Stem cell research and remains among the top cell therapy companies in the world bringing therapeutic products for difficult to treat diseases. It has made Invent-in-India a reality”.

**Mr. BN Manohar, CEO of Stempeutics said,** “Our Company’s mission is to “Develop innovative stem cell products addressing major unmet medical needs with an India first, global next approach”. In the past 10 years, we have developed cutting edge technology to bring stem cell products in India to physicians who now have an off-the-shelf stem cell therapy in their hand to fight diseases like Critical Limb Ischemia. With Kemwell’s investments we plan to register for additional indications for Stempeucel®, expand into the developed markets, and further develop our pipeline.”

#### **About Stempeutics:**

Stempeutics is an advanced clinical stage Biotech Company based out of Bangalore. It was founded by Manipal Education and Medical Group (MEMG) in 2006 and later entered into an alliance with Cipla in 2009. Stempeutics strength lies in developing innovative stem cell products by nurturing cutting edge research and clinical applications through dedicated efforts of its highly qualified team. Its goal is to develop novel stem cell drugs addressing major unmet medical needs with an India first global next approach.

For more information pl visit [www.stempeutics.com](http://www.stempeutics.com)

#### **About Kemwell Biopharma:**

Kemwell is a contract development and manufacturing organization serving the pharmaceutical industry offering a comprehensive service for development and cGMP manufacturing of large molecule products (drug substance and drug product). Kemwell has more than 30 years of experience in CDMO industry dealing with FDA, PMDA and other regulatory authorities. In its current state-of-the-art facility, Kemwell develops and manufactures cell culture biological products up to cGMP scale of 2000L batches. Kemwell has successfully supplied products for IND filings in the US and has recently supplied cGMP drug substance for a Phase 3 trial in the US.

For more information pl visit [www.kemwellbiopharma.com](http://www.kemwellbiopharma.com)

**About Manipal Education & Medical Group:**

Manipal Education and Medical Group (MEMG) is one of the leaders in the country, in the field of education and healthcare services, with a global footprint. MEMG, through its subsidiaries, provides education and healthcare services in India and internationally. It manages universities and professional institutions, including medical colleges, teaching hospitals, and medical science and technology institutions through which it provides bachelor's and master's degree programs in various streams. The company also manages healthcare institutions, super-specialty care hospitals, rural maternity and child welfare homes. MEMG International India Pvt. Ltd. was founded in 1953 and is based in Bengaluru, India with education colleges and campuses in Antigua, Dubai, Malaysia, and Nepal.

For further information pl visit [www.manipalgroup.com](http://www.manipalgroup.com)

Stempeutics Research Media Contact:

Dr. Raviraja N S

Corporate Communications

Mobile No: +91 9900239214

E Mail id: [raviraja.ns@stempeutics.com](mailto:raviraja.ns@stempeutics.com)

[www.stempeutics.com](http://www.stempeutics.com)